GLGeoffroy Liegeon

Geoffroy Liegeon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Geoffroy Liegeon has a total of 215 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Satisfaction and Treatment Burden Among Early Adopters of Long-Acting Injectable Cabotegravir-Rilpivirine With and Without Viremia in Three US Ryan White Clinics

    by Katerina A Christopoulos, Alex Beckert, Caleb McCracken, Kaylin Dance, Sophie Plotkin, Lauren F Collins, Moira C McNulty, Matthew D Hickey, Mallory O Johnson, Aaloke Mody, et al.

    Among underserved people with HIV with a median of one year of long-acting cabotegravir-rilpivirine use, including those starting with viremia due to adherence challenges, we found higher satisfaction and lower treatment burden compared to daily oral ART, although nearly half preferred another dosing modality and/or a longer dosing interval.

  • Open Access

    Overlooked risk factors for European autochthonous strongyloidiasis, Paris, France

    by Benoît Heid-Picard, Marion Parisey, Jade Ghosn, Samia Hamane, Stéphane Bretagne, Geoffroy Liegeon, Nathalie De Castro, Yazdan Yazdanpanah, Nathan Peiffer Smadja, Sandrine Houzé, et al.

  • Open Access

    Renal Outcomes in People With HIV-1 and Renal Impairment Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide: Integrated Analysis From 9 Phase 3/3b Clinical Trials

    by Frank A Post, David Wohl, Geoffroy Liegeon, Indira Brar, Debbie Hagins, Yazdan Yazdanpanah, Anchalee Avihingsanon, Hui Liu, Keith Aizen, Jason T Hindman, et al.

    Among 1069 people with HIV-1 and mild to moderate renal impairment at baseline treated with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) across 9 clinical trials, renal function remained generally stable over follow-up of up to 240 weeks. Renal adverse events were infrequent, and discontinuation due to renal toxicity was rare.


  • Open Access

    Creatine supplementation confounding kidney function monitoring in tenofovir-based HIV preexposure prophylaxis

    by Yanis Tamzali, Martin Siguier, Jordan Desenclos, Pierre Galichon, Geoffroy Liegeon, Jeremy Zeggagh, Cyril Mousseaux, Jean‑Philippe Haymann, Laurent Mesnard, Emmanuel Letavernier, et al.

    Introduction: Tenofovir‑based preexposure prophylaxis (PrEP) is widely used and proved its efficacy for HIV prevention, and kidney function monitoring relies primarily on serum creatinine-based estimation of the glomerular filtration rate (eGFR). Oral creatine supplementation can increase serum creatinine without reflecting a true reduction in glomerular filtration rate (GFR). As is not widely known it can potentially lead to inappropriate PrEP discontinuation. Case description: We report three clinical cases of healthy men who have sex with men (MSM) receiving tenofovir‑based PrEP who referred to a nephrologist for declining serum creatinine‑based eGFR while taking oral creatine supplements for muscle development associated with sport. Serum creatinine compared to cystatin C-based eGFR was performed and measured GFR (DTPA‑Tc99) when available to assess kidney function. In the first case, a 45‑year‑old man taking daily PrEP and oral creatine presented with elevated serum creatinine (1.39 mg/dl) and reduced creatinine‑based eGFR (61 ml/min/1.73 m2). Cystatin C-based eGFR indicated a preserved kidney function (83 ml/min/1.73 m2). After discontinuing creatine, serum creatinine decreased to 1.17 mg/dl and creatinine‑based eGFR improved to 75 ml/min/1.73 m2, aligning with cystatin C estimates. In the second case, a 38‑year‑old man using on‑demand PrEP and taking oral creatine referred to the nephrologist with a decline in creatinine‑based eGFR from 112 to 78 ml/min/1.73 m2 over four years. Despite this apparent decline, measured GFR was in range (113 ml/min/1.73 m2) aligned with cystatin C-based eGFR (107 ml/min/1.73 m2). In the third case, a reduced creatinine-based eGFR was observed in a 41‑year‑old man who was taking daily PrEP with the supplement. Moreover, a one‑day interruption of creatine prevented this artifact, with both serum creatinine and cystatin C returning to normal ranges. A last serum creatinine measurement performed four days after creatine was reintroduced reduced the eGFR by 20 ml/min/1.73 m2. Discussion: Oral creatine supplementation, frequently used by tenofovir-based PrEP users, can artifactually elevate serum creatinine and lead to underestimation of kidney function. Cystatin C-based eGFR is not affected by creatine and so its use can be an easy tool for PrEP prescribers for an accurate assessment of kidney function. Its use may prevent risky and unjustified PrEP interruptions and reduce nephrological referral. Creatine metabolism permits a withdrawal one day before the PrEP follow-up lab tests.

  • Impact sur la fonction rénale du ténofovir disoproxil utilisé en prévention des infections par le VIH ou par le virus de l'hépatite B

    by Geoffroy Liegeon

    De nombreuses études montrent que l'utilisation du ténofovir disoproxil (TDF) à titre prophylactique permet de réduire très significativement le nombre de nouvelles contaminations par le VIH et par le virus de l'hépatite B. Cependant, le risque de survenue d'évènements indésirables rénaux sévères peut ralentir la mise en œuvre de ces nouvelles stratégies de prévention. Ce travail de thèse s'est donné pour objectif d'évaluer l'impact rénal du TDF utilisé dans le cadre de la prophylaxie pré-exposition (PrEP) du VIH et dans la prévention de la transmission mère-enfant (PTME) du VHB afin d'élaborer des recommandations de suivi et de surveillance de la fonction rénale sous cette prophylaxie.L'étude de cohorte menée sur les 3000 usagers de PrEP suivis à l'hôpital Saint-Louis à Paris démontre que le risque d'insuffisance rénale aigue sous TDF est faible et se concentre spécifiquement dans le groupe des utilisateurs âgés de plus de 50 ans et/ou ayant un débit de filtration glomérulaire estimé (DFGe) inférieur à 90 mL/min au moment d'initier la prophylaxie. Ces utilisateurs ont pu continuer à utiliser la PrEP, suite ou non à un arrêt temporaire, avec un faible taux de récidive de l'insuffisance rénale. L'analyse des données issues de l'essai clinique contrôlé randomisé contre placebo Ipergay et de la cohorte d'usagers de PrEP ANRS-Prévenir en Ile de France montrent que la PrEP « à la demande » chez les hommes ayant des rapports sexuels avec des hommes améliore la tolérance rénale de cette prophylaxie. Ce type de schéma intermittent peut permettre de réduire le risque de toxicité rénale chez les utilisateurs ayant des facteurs de risque d'insuffisance rénale. Les données de ces trois études combinées aux données bibliographiques permettent de suggérer des recommandations simples de suivi de la fonction rénale chez les usagers PrEP. Ces recommandations soulignent la nécessité d'individualiser la surveillance de la fonction rénale. Elles permettent d'envisager des stratégies de démédicalisation visant à augmenter significativement le nombre d'usagers en élargissant leur suivi à des professionnels de santé non médicaux tout en diversifiant les lieux d'obtention de la PrEP. Dans le cadre de la PTME de l'hépatite B, nous avons évalué spécifiquement le risque de tubulopathie maternelle, compte-tenu de l'effet potentiellement très délétère qu'une telle atteinte aurait sur la santé maternelle et infantile. En utilisant des marqueurs précoces d'atteinte tubulaire sur des prélèvements d'urines recueillis dans un essai clinique contrôlé randomisé en double insu contre placebo conduit en Thaïlande (iTAP), nous montrons que l'utilisation du TDF n'est pas associée à une augmentation significative du risque de tubulopathie et que le TDF peut être utilisé sans risque durant le troisième trimestre de grossesse et l'allaitement. Cela confirme que la PTME de l'hépatite B chez les femmes infectées à haut risque de transmission peut être mise en œuvre par des non-spécialistes dans de nombreux contextes.En conclusion, le risque de toxicité rénale lié à l'utilisation du TDF dans la prévention du VIH et de l'hépatite B ne doit pas être considéré comme un obstacle à la mise en œuvre partout dans le monde de ces stratégies de prévention très prometteuses notamment dans les pays à faibles ressources où la surveillance régulière de la fonction rénale n'est pas possible.

  • Open Access

    Safety and Tolerability of Oral Islatravir Once Monthly as Pre-exposure Prophylaxis in Cisgender Men and Transgender Women Who Have an Elevated Likelihood of HIV-1 Exposure: Results From the IMPOWER-24 Randomized Phase 3 Study

    by Raphael J Landovitz, Yvett Pinedo, Federico Hinestrosa, Gordon E Crofoot, Cynthia Brinson, Susan Buchbinder, Jean-Michel Molina, Ronnie M Gravett, James B Brock, Moti N Ramgopal, et al.

    Background: Islatravir once monthly (qm), a nucleoside reverse transcriptase translocation inhibitor with a long half-life, was evaluated for safety and tolerability in cisgender men and transgender women who have sex with men and are at increased likelihood of HIV-1 (HIV) exposure. Methods: IMPOWER-24 (NCT04652700) was a double-blind, Phase 3 study. Participants were randomized 2:1 to islatravir 60 mg oral qm or emtricitabine (FTC; 200 mg) coformulated with either tenofovir disoproxil (245 mg) or tenofovir alafenamide (TAF; 25 mg) once daily (qd). After ∼9 months, blinded islatravir was discontinued due to lymphocyte reductions; participants were offered open-label comparator for 20 months. Results: In total, 494 participants were enrolled (328 islatravir; 166 comparator): 91.5% were cisgender men, 41.7% were White, and median age was 27 years. Mean blinded dosing duration was 4.7 months (islatravir) versus 4.3 months (comparator). Overall, 211 participants (64.3%) in the islatravir group and 128 (77.1%) in the comparator group had ≥1 adverse event (AE). Most AEs were mild or moderate, with 1 AE leading to product discontinuation (islatravir; gastroesophageal reflux). Serious AEs occurred in <2%; none were related to study product. Change in total lymphocytes in the islatravir group at Month 3 was −7.4%; a trend toward recovery was observed after islatravir was stopped. Mean total lymphocytes remained within normal range. No HIV infections occurred in either group during the double-blind phase. Conclusions: Islatravir qm was generally well tolerated; decreases in total lymphocytes were observed with islatravir. Original primary efficacy objectives were not assessed due to early study stoppage.


  • Antimicrobial-Resistant Neisseria gonorrhoeae Infections in Men Using Doxycycline Postexposure Prophylaxis: A Substudy of the ANRS 174 DOXYVAC Trial

    by Béatrice Bercot, Lambert Assoumou, François Caméléna, Chloé Voitichouk, Manel Mérimèche, Moussa Ouattara, Geoffroy Liegeon, Aissata Didine Kaba, Victoria Manda, Mary Mainardis, et al.

    Background: Prevention of bacterial sexually transmitted infections prevention by doxycycline postexposure prophylaxis (DoxyPEP) in men who have sex with men has raised concerns about antimicrobial resistance (AMR). We studied the impact of DoxyPEP on Neisseria gonorrhoeae (gonococcus [GC]) AMR in the ANRS 174 DOXYVAC trial. Methods: Men who have sex with men and were on human immunodeficiency virus preexposure prophylaxis randomized to DoxyPEP (n = 362) or no–postexposure prophylaxis (PEP) (n = 183) arms were tested for GC at baseline and every 3 months thereafter, by culture and nucleic acid amplification test (NAAT). Minimum inhibitory concentrations (MICs) were determined with Etest (bioMérieux) and interpreted according to European Committee on Antimicrobial Susceptibility Testing guidelines. We performed whole-genome sequencing and/or polymerase chain reaction sequencing on GC isolates and NAAT-positive samples, using Fisher exact tests for comparisons. Results: From January 2021 to February 2023, MICs were determined for 78 GC isolates, and 233 NAAT-only GC-positive samples were analyzed to identify the molecular determinants of resistance. All GC isolates were resistant to tetracycline with a significant increase in the rate of high-level tetracycline resistance mediated by the tetM gene in the DoxyPEP arm compared with the no-PEP arm (35.5 vs 12.5%, respectively; P = .043). The MICs of ceftriaxone, fluoroquinolones, and azithromycin were similarly distributed in the DoxyPEP and no-PEP arms. All GC isolates were susceptible to ceftriaxone and cefixime, but isolates with decreased susceptibility to cefixime linked to the mosaic penA34.007 allele were more frequent in the DoxyPEP arm than the no-PEP arm (32.3% vs 10.0%, respectively; P = .033). Conclusions: DoxyPEP use was associated with a significant increase in high-level tetracycline resistance and decreased susceptibility to cefixime in GC. AMR should therefore be closely monitored when using this strategy.


  • A Survey Study of Concerns and Attitudes Toward Doxycycline Postexposure Prophylaxis Among Bathhouse-Affiliated Individuals in the United States and Canada

    by Michael Wasz, Aniruddha Hazra, Laura Rusie, Geoffroy Liegeon, Nirmalpal Sachdev, Irina Tabidze, Supriya D. Mehta

    This study assesses doxycycline postexposure prophylaxis awareness, perceptions, and concerns among bathhouse-affiliated individuals. Antimicrobial resistance, adverse effects, and accessibility were primary concerns. Partnerships with bathhouses present opportunities to address these barriers through targeted education, enhancing acceptance and promoting doxycycline postexposure prophylaxis’s effectiveness in preventing sexually transmitted bacterial infections.

  • Eligibility and factors associated with long-acting injectable cabotegravir-rilpivirine initiation in an urban academic HIV clinic

    by Geoffroy Liegeon, Eleanor Friedman, Christopher Kaperak, Paul Djuricich, Alicia Dawdani, Sophie Plotkin, Jessica Schmitt, Aniruddha Hazra, Katerina A Christopoulos, John A Schneider, et al.

    Objectives: This study aimed to assess eligibility for long-acting injectable (LAI) cabotegravir/rilpivirine among people with HIV (PWH), identify factors associated with initiation and examine provider prescribing patterns in an urban academic clinic in the USA. Patients and methods: We conducted a retrospective cohort analysis among PWH at the University of Chicago HIV clinic from 1 January 2021 to 31 May 2023. Eligibility criteria for LAI cabotegravir/rilpivirine included HIV-1 RNA <50 copies/mL for ≥3 months, no active hepatitis B, no resistance to rilpivirine or cabotegravir and no treatment failure history. Logistic regression identified factors associated with initiation among eligible PWH as well as prescribing patterns of providers. Results: Of 657 PWH, 413 (63%) were eligible for LAI cabotegravir/rilpivirine. Median age was 45, 33% were women, 84% Black, 70% had permanent housing, 52% employed, 56% on Medicaid, 9% had active substance use and 26% had psychiatric comorbidities. Among those eligible, 64 PWH (15%) initiated LAI cabotegravir/rilpivirine. In multivariate analysis, younger age was the only factor associated with LAI cabotegravir/rilpivirine initiation [OR 0.96, 95% CI (0.94, 0.99), P = 0.01]. Prescribing patterns varied widely among the 13 providers, with initiation rates ranging from 0% to 33% (P < 0.001). Two providers, covering 40% of eligible patients, were responsible for 70% of initiations. Conclusions: In our urban HIV clinic, 63% of PWH were eligible for LAI cabotegravir/rilpivirine, and 15% initiated it within 2.5 years post-approval. Age and provider patterns significantly influenced LAI cabotegravir/rilpivirine uptake. Understanding factors driving LAI cabotegravir/rilpivirine uptake is key to expanding its reach.

  • PrEP Prescriptions at 2 Federally Qualified Health Centers

    by Eleanor E. Friedman, Joseph A. Mason, Samantha A. Devlin, Geoffroy Liegeon, Amy K. Johnson, Jodi Simon, Daniel Parras, Katherine Chung-Bridges, Maria Pyra, Lisa R. Hirschhorn, et al.

    Background: Preexposure prophylaxis (PrEP) is a medication that prevents HIV infection. However, PrEP is not equally used by all who would benefit. We examined PrEP disparities by comparing the number of sexually transmitted infections (STIs) and PrEP prescriptions across sex, race, and ethnic groups from 2 federally qualified health centers (FQHCs) in Pinellas County, Florida, and Chicago, Illinois. Methods: We obtained limited electronic medical record data from January 1, 2023, to December 31, 2023, and identified STI diagnoses (gonorrhea, chlamydia, or syphilis) and PrEP initiation prescriptions. We calculated the PrEP initiation rate for different sex, race, and ethnicity groups; the rate difference in PrEP initiations for each demographic group compared with that in White men; and the ratio of PrEP initiations to STI diagnoses in each group. Results: Out of a total of 63,591 patients, 1208 (1.9%) were diagnosed with an STI and 88 (0.1%) had PrEP initiation prescriptions. There was no rate difference per 100 people in PrEP initiation among Black and White men, but Hispanic men (−0.11), Black women (−0.14), White women (−0.24), and Hispanic women (−0.25) demonstrated PrEP disparities. When examining the ratio of PrEP initiations to STI diagnoses in each group, White men had (0.42) PrEP initiations per STI diagnosis, with much lower ratios seen for Hispanic men (0.2), Black men (0.13), Black women (0.04), White women (0.03), and Hispanic women (0.02). Conclusions: White men had the highest rate of initial PrEP prescriptions. Men overall received PrEP between 3 and 21 times more frequently per STI diagnosis than women.